Zacks Research Increases Earnings Estimates for Stryker

Stryker Co. (NYSE:SYK - Free Report) - Research analysts at Zacks Research boosted their FY2024 EPS estimates for Stryker in a report released on Monday, November 18th. Zacks Research analyst I. Bandyopadhyay now expects that the medical technology company will earn $12.03 per share for the year, up from their prior forecast of $11.91. The consensus estimate for Stryker's current full-year earnings is $12.06 per share. Zacks Research also issued estimates for Stryker's Q4 2024 earnings at $3.85 EPS, Q2 2025 earnings at $3.22 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.41 EPS and FY2026 earnings at $14.60 EPS.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the company posted $2.46 earnings per share. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis.

SYK has been the subject of a number of other reports. Robert W. Baird increased their price objective on Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Canaccord Genuity Group raised their target price on shares of Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. UBS Group upped their price target on shares of Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. Wolfe Research assumed coverage on Stryker in a research note on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price objective for the company. Finally, BTIG Research raised their target price on Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $393.65.

Stryker Trading Down 0.2 %

NYSE SYK opened at $388.66 on Wednesday. Stryker has a one year low of $285.79 and a one year high of $398.20. The firm has a market cap of $148.16 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a 50 day simple moving average of $365.08 and a 200-day simple moving average of $348.40.

Institutional Trading of Stryker

A number of hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC raised its stake in Stryker by 78.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company's stock valued at $45,260,000 after purchasing an additional 58,673 shares during the last quarter. OFI Invest Asset Management grew its position in Stryker by 3,210.9% during the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company's stock worth $1,062,000 after purchasing an additional 3,243 shares during the last quarter. Tidal Investments LLC increased its position in Stryker by 14.2% in the 1st quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company's stock valued at $4,853,000 after acquiring an additional 1,681 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Stryker by 2.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company's stock valued at $210,289,000 after purchasing an additional 16,504 shares during the last quarter. Finally, Fiera Capital Corp increased its stake in Stryker by 42.1% in the 2nd quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company's stock valued at $5,687,000 after buying an additional 4,948 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the sale, the vice president now owns 10,042 shares of the company's stock, valued at $3,685,213.16. The trade was a 42.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,381 shares of company stock worth $24,825,275. 5.50% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.